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Abstract. Vietnam is participating in a global de-worming effort that aims to treat 650 million school children
regularly by 2010. The treatment used in Vietnam is single dose oral mebendazole (Phardazone) 500 mg. We tested the
efficacy of single dose mebendazole 500 mg in the therapy of hookworm infection in a randomized double-blind
placebo-controlled trial among 271 Vietnamese schoolchildren. The treatment efficacy of single dose mebendazole in
children did not differ significantly from placebo, with a reduction in mean eggs per gram of feces relative to placebo
of 31% (95% CI −9 to 56%, P 0.1). In light of these findings we then carried out a similar randomized trial comparing
triple dose mebendazole, single dose albendazole, and triple dose albendazole against placebo in 209 adults in the same
area. The estimated reduction in mean post-treatment eggs per gram of feces relative to placebo was 63% (95% CI
30–81%) for triple mebendazole, 75% (47–88%) for single albendazole, and 88% (58–97%) for triple albendazole. Our
results suggest that single dose oral mebendazole has low efficacy against hookworm infection in Vietnam, and that it
should be replaced by albendazole. These findings are of major public health relevance given the opportunity costs of
treating entire populations with ineffective therapies. We recommend that efficacy of anti-helminth therapies is pilot
tested before implementation of national gut worm control programs.
INTRODUCTION
Worldwide more than 2 billion people are chronically in-
fected with soil-transmitted helminths (STH): Ascaris lumbri-
coides, the hookworms (Ancylostoma duodenale and Necator
americanus), or Trichuris trichiura.1 Especially in children,
anemia, growth impairment, poor school attendance, and de-
lay in intellectual development are established consequences
of STH infection, resulting in a significant burden on health
care and financial resources in low-income countries.1–7 Ill
health secondary to intestinal helminth infection is said to be
preventable through regular deworming.2–7 As a conse-
quence, the World Health Assembly urged the international
community to take firm action against STH infections in 2001.
Since then, the ‘Partners for Parasite Control’ (WHO mem-
ber states, the World Food Program, UNICEF, the World
Bank, research institutions, and non-governmental organiza-
tions) set out to deworm 650 million school-aged children at
risk of STHs and schistosomiasis regularly by 2010.1 In Viet-
nam, where an estimated 6 million school-aged children are
infected with a STH, the recommended STH control cam-
paign comprises periodic mass treatment with single dose oral
mebendazole (Phardazone 500 mg), given either once a year
in areas with STH prevalences between 20% and 50%, or
twice a year in areas with STH prevalences above 50%.8,9
During the 2005–2006 school year, the National Institute of
Malariology, Parasitology, and Entomology (NIMPE) in col-
laboration with WHO will be treating 2.5 million schoolchil-
dren in Vietnam, and the plan is to gradually extend the
program.10
As part of a randomized placebo-controlled trial of the
effect of treating hookworm infection on the occurrence and
severity of allergic disease,11 we assessed the effectiveness of
single dose Phardazone 500 mg in hookworm-infected Viet-
namese children. In the light of our findings, we carried out a
further randomized double-blind placebo-controlled trial,
comparing the effectiveness of multiple dose mebendazole
with single or multiple dose albendazole in Vietnamese
adults.
METHODS
Study 1. We invited all 309 6- to 11-year old children at-
tending two primary schools in a rural commune in Khanh
Hoa province, central Vietnam. Those who were not systemi-
cally ill or known to be allergic to the trial intervention were
eligible to take part. The children and their parents were
visited by local health care workers, specifically trained for
the project, and given a disposable container with clear in-
structions on how to provide a fresh stool sample the next day
together with an information leaflet and consent form. The
following day, provided informed consent was granted, the
sample was collected and the child assigned at random in
permuted blocks of 10 and stratified by school, to receive
either single dose mebendazole (Phardazone) 500 mg or
matching placebo (Pharbaco [Central Pharmaceutical Com-
pany No. 1], Hanoi, Vietnam). The randomization code was
generated independently at the Oxford University Clinical
Research Unit in Ho Chi Minh City, and the randomization
sequence was subsequently concealed from study partici-
pants, health care workers administering the treatments, and
those assessing the main outcomes by ensuring that all treat-
ments were packaged by the Oxford University Clinical Re-
search Unit in sealed opaque consecutively numbered enve-
lopes. Both mebendazole and placebo were manufactured for
the study with the same equipment. Administration of the
tablets was done under direct supervision of the field workers
to ensure complete adherence. Placebo tablets were identical
in shape, smell, and color to the active treatments, and neither
the study participants nor those administering the treatments
knew which was the active treatment. Two weeks after ad-
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ministration of the study medications, a second stool sample
was collected from each child. All stool samples were trans-
ported to the local district hospital, where they were exam-
ined for parasite eggs both qualitatively and quantitatively in
terms of eggs per gram (epg) feces by salt flotation method
with McMaster counting chambers within a maximum of 6
hours after collection. For negative slides a second slide was
examined. All laboratory technicians were blind to treatment
allocation. The trial mebendazole (Phardazone) and me-
bendazole placebo were independently quality tested by the
Bureau of Food and Drugs, Department of Health, Republic
of the Philippines, to assess whether they met international
quality standards.
Study 2. All 247 adults aged 16 and older living in one
village in the same geographical area were invited to partici-
pate in our second study. The same methods were used as in
the first study but this time, there were four comparison
groups: single dose mebendazole placebo, mebendazole
(Phardazone) 500 mg daily for three days, albendazole 400
mg single dose (Mekozetel, Mekophar Chemical Pharma-
ceutical Joint Stock Company, Ho Chi Minh City, Vietnam),
or albendazole 400 mg daily for three consecutive days. Ran-
domization was generated and concealed as in the first study,
and permuted blocks of 20 were used. Although field workers
and study participants could tell whether they were allocated
to the one of the two groups receiving single treatment or
triple treatments, those assessing the stool analysis outcomes
were masked to the intervention groups throughout the study.
Villagers with a systemic illness, who were pregnant, or were
known to be allergic to one of the intervention drugs were
excluded. Fecal egg counts were carried out just before and 2
weeks after therapy, as in Study 1. We also performed a vali-
dation study, comparing McMaster salt flotation in the field
with ether sedimentation as gold standard. Ether sedimenta-
tion was done independently on 151 samples from the adult
study. Fresh stool samples were preserved in 10% formalin
and then transported to IMPE Ho Chi Minh City. The labo-
ratory technicians at IMPE Ho Chi Minh City were blind to
the results with salt flotation.
All data were double entered using SPSS Data Entry Sta-
tion 4.0. The primary endpoint for both studies was parasite
intensity as measured by percent decline in arithmetic mean
epg after treatment, relative to arithmetic mean post-
treatment placebo.12 A secondary endpoint was cure from
hookworm infection (i.e., loss of hookworm eggs from feces
in those infected at baseline). Cure rate was analyzed as a
binary variable by logistic regression. To control for any
change in mean epg in the placebo group, reduction in egg
count was calculated as the percentage mean reduction com-
pared with post-treatment egg counts in the placebo group.
Egg counts were highly overdispersed, and were therefore
analyzed by generalized negative binomial regression. This
approach assumes a negative binomial error structure for the
dependent variable and a log link, and allows both the mean
and the negative binomial parameter (ln) to be depen-
dent on the explanatory variable (treatment group). The de-
pendent variable was the number of eggs counted, with the
weight of feces examined included as an offset. Post-
treatment egg counts were analyzed in those with pre-
treatment egg count above zero. Differences between treat-
ment and placebo groups were analyzed by simple linear con-
trasts. For analysis of the effect of pretreatment burden on
efficacy in the second study, pretreatment burden was coded
as 0  light (<2000 epg), 1  medium (2000–3999 epg) or
2  heavy (>3999 epg), according to WHO guidelines.1 The
analysis was then repeated, including burden class as a con-
tinuous covariate, to examine for interaction between burden
class and treatment. All analysis was performed using Stata
9.1. An intention-to-treat analysis was planned in the event of
study dropouts. Ethics approval for the two studies was
granted by the University of Nottingham Research Ethics
Committee and the Scientific Committee of Khanh Hoa Pro-
vincial Health Service, Vietnam. Local doctors and commu-
nity leaders were involved in the design and conduct of the
study throughout.
RESULTS
Study 1 was carried out in June 2005. Of the 309 eligible
children, 271 (88%) participated, of whom 134 received pla-
cebo and 137 mebendazole; 38 children did not participate
due to absence from school on the relevant date. The overall
prevalence of hookworm infection in the study group at base-
line was 62%, and the mean intensity was 175 epg (range
0–3800 epg). The species of hookworm present was not iden-
tified, but previous studies have shown that Necator america-
nus is the predominant species in our study area (see Hoang
Thi Kim, Nguyen Thi Viet Hoa, Marchand R, 1995. Intestinal
worms, malaria, and anemia in Khanh Phu. Unpublished re-
port NIMPE, Hanoi). Other baseline characteristics of par-
ticipants are summarized in Table 1. In addition, we found 16
children (6%) with Ascaris lumbricoides infection, but num-
bers in each treatment group were too small to reliably ana-
lyze treatment efficacy. No participants were lost to follow-up
and all were included in the final analysis. As shown in Table
1, there was no significant difference between treatments in
the proportion of infected children cured at 2 weeks (33%
(26/78) in the placebo group and 38% (34/90) in the mebenda-
zole group. Efficacy in terms of percentage reduction in arith-
metic mean eggs per gram feces relative to placebo was also
not significantly different (31%, 95% CI −9 to 56%).
Study 2 was carried out in August 2005. Of the 247 eligible
adults, 209 (85%) took part in the second study, of whom 54
received three doses of mebendazole over 3 days, 54 single
dose albendazole, 47 three doses of albendazole, and 54 single
dose mebendazole placebo tablets. Reasons for non-
participation were refusal (N  26), absence from the village
(N  5), illness (N  5), and pregnancy (N  2); 91% of
participants were infected with hookworm at baseline, with a
mean intensity of 1283 epg (range 0–17850 epg). Fourteen
individuals had heavy infections (>3999 epg).1 Six participants
(3%) were infected with either Ascaris or Trichuris as well as
hookworm infection. No participants were lost to follow-up
and all were included in the analysis. At the end of the 2-week
period, the cure rates were 26% (13/50) for three dose me-
bendazole, 45% (21/47) for single dose albendazole, 79% (34/
43) for three dose albendazole, and 35% (18/51) for placebo.
Only the triple dose albendazole course was significantly su-
perior to placebo in terms of cure (P < 0.001). The estimated
reduction in arithmetic mean post-treatment eggs per gram of
feces relative to placebo was 63% (95% CI 30–81%), 75% (47–
88%), and 88% (58–97%) for triple dose mebendazole, single
dose albendazole, and triple dose albendazole, respectively.
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Adjustment for age and sex did not alter any of these findings.
When the analysis was repeated including the interaction be-
tween pretreatment burden class (light, medium, or heavy)
and treatment, there was a non-significant increase in efficacy
with increasing pretreatment burden (Likelihood ratio test,
2  4.32, df  3, P  0.23). All drugs, single or triple dose
were equally well tolerated. No adverse events were reported
in either study.
Comparison of egg counting techniques showed that 88.7%
of samples (134/151) were positive by salt flotation, compared
with 90.7% (137/151) by ether sedimentation, and 95.4%
(144/151) by either method. Arithmetic mean egg counts were
1332 epg for salt flotation and 1723 epg for ether sedimenta-
tion. In addition, the Bureau of Food and Drugs, Department
of Health, Republic of the Philippines, confirmed that our
mebendazole met international quality criteria as set out in
the US Pharmacopoeia.
DISCUSSION
Main findings. The first study demonstrated that single
dose generic mebendazole (Phardazone) was not signifi-
cantly superior to placebo against hookworm in rural Viet-
namese children, with an estimated cure rate 5% greater than
placebo and a mean reduction of egg intensity 31% better
than placebo. For mass treatment programs, the most impor-
tant measure is reduction in intensity, as programs aim to
reduce rather than eliminate parasites. Because single oral
dose Phardazone is currently being used for the ‘Partners for
Parasite Control’ campaign in Vietnam, the low efficacy of
this regimen is of major public health concern. As albenda-
zole has a higher efficacy against hookworm infection than
mebendazole, we also compared single and triple dose al-
bendazole with triple dose mebendazole in our second
study.13,14 We found that all three treatments were better
than placebo in terms of reduction of fecal egg count, with
triple dose albendazole being the most efficacious. Although
our study suggests that albendazole used on three consecutive
days has the highest efficacy and despite the relatively low
efficacy of single dose albendazole (75%) compared with
other studies worldwide, single dose albendazole might be a
reasonable compromise between efficacy and costs for mass
treatment in Vietnam.13,14 Three-day treatment regimens are
not appropriate for mass control programs, and were only
included in the current study as possible regimens for our
asthma study.
Study strengths and limitations. Strengths of our two re-
lated studies include the randomized controlled design, blind-
ing of the outcome assessment, use of placebos, high partici-
pation rates, and complete follow-up of all those randomized.
Although participant numbers were modest, resulting in rela-
tively wide confidence intervals, the upper 95% confidence
limit for the observed 31% efficacy of single dose mebenda-
zole relative to placebo was only 56%, which is unlikely to be
clinically useful for a national helminth control program. Fe-
cal helminth egg counts are known to be highly variable.15
Although variability can be reduced by performing repeated
egg counts over a number of days, such variation should not
lead to differential bias. Egg counts may also vary over time
in untreated individuals, as shown by the decline in egg counts
post-treatment in the placebo group. This may reflect both
regression to the mean and real variation in egg count
through time. Similar observations have been made in other
studies, emphasizing the importance of comparing efficacy to
a control group.16,17 Another potential limitation in general-
izing our findings is that the second study was conducted
among adults.14 This was a necessity because by that time all
children in the study area had already been enrolled in our
main clinical trial on hookworm-allergy links. Moreover, the
pretreatment burden was much higher in the second study.
The effect of pretreatment burden on efficacy is unclear, with
both increases and decreases in efficacy with increasing bur-
den reported.13,14 Here, we found a slight, but non-significant,
increase in efficacy with increasing burden, although the sta-
tistical power to detect such an effect was small. Thus it is
possible that efficacy of mebendazole was underestimated in
the first study, compared with higher intensity populations. In
contrast to other reported studies of drug efficacy, which typi-
TABLE 1
Baseline characteristics and baseline and post treatment hookworm eggs per gram (egp) by treatment group, and estimated percentage efficacy
relative to placebo for both trials
Study 1 (children) Study 2 (adults)
Placebo
Single dose







N treated 134 137 54 54 54 47
Male/female 57/77 65/72 25/29 25/29 25/29 28/19
Mean age 9 9 37 35 37 33
Age range 7–11 7–11 18–68 16–75 16–65 17–65
Hookworm positive at baseline 58% 66% 0.2 94% 93% 87% 91% 0.6
(78/134) (90/137) (51/54) (50/54) (47/54) (43/47)
Cure rate 33% 38% 0.5 35% 26% 45% 79%¶ < 0.001
(95% CI) (23–45) (28–49) (22–50) (15–40) (30–60) (64–90)
(n neg/pos at baseline) (26/78) (34/90) (18/51) (13/50) (21/47) (34/43)
Baseline mean hookworm epg* 306 263 0.3 1068 2210‡ 1120 1173 0.004
Posttreatment mean hookworm epg* 181 126 0.11 930 342‡ 230¶ 109¶ 0.0004
Reduction in mean epg relative to
pretreatment epg 41% 52% 13% 85% 79% 91%
Reduction in mean epg relative to
placebo (95% CI) 31% (−9, 56) 63% (30, 81) 75% (47, 88) 88% (58, 97)
* Arithmetic mean in those positive for hookworm at baseline.
† Test for difference between groups.
‡ Significantly different from placebo (P < 0.005); ¶(P < 0.001).
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cally use Kato-Katz thick smears to quantify egg counts, we
used a salt-flotation technique. This is unlikely to have af-
fected the results, as salt flotation showed similar sensitivity to
the more widely used formol-ether sedimentation. Formol-
ether has been shown to have similar, or reduced, sensitivity
to Kato-Katz.18,19
Possible reasons for low efficacy. Drug quality or manufac-
turer has been reported to affect mebendazole efficacy in
some, but not other, studies.20,21 However, the tablets we
used were independently quality tested and met international
standards. Efficacy may also vary geographically.13 The rea-
sons for this are unclear, but it highlights the importance of
testing the effect of anthelmintic treatment locally prior to the
launch of large control campaigns.22 There is now also grow-
ing concern about resistance to benzimidazoles.23,24 Resis-
tance has been widely reported in livestock parasites after
frequent de-worming, and although benzimidazole resistance
has so far not been conclusively demonstrated in human
hookworms, drug resistance may explain the apparent decline
in mebendazole efficacy seen after repeated mass treatment
with mebendazole.25,26 Lack of mebendazole treatment effi-
cacy in a previously untreated population has also been re-
ported from Mali.16 To our knowledge, there are no previous
published reports of mebendazole efficacy against hookworm
in Vietnam, though a recent study from neighboring Cambo-
dia reported a significant decline in hookworm egg counts
after twice-yearly mebendazole.27 Although drug resistance
as a consequence of drug selection pressure seems very un-
likely in our study population without a history of previous
mass treatments and very limited availability of over-the-
counter anthelmintics, further monitoring of the parasite
population for resistance using egg hatch assays or molecular
genetics may be prudent.28,29
Study implications. Single dose mebendazole 500 mg and
single dose albendazole 400 mg are recommended by the
‘Partners for Parasite Control’ initiative for hookworm con-
trol. Of the two, mebendazole is often chosen due to its
slightly lower price.30 Our findings suggest that single dose
mebendazole may lack suitable efficacy for the intended pur-
pose in Vietnam, and continued use of mebendazole should
depend on further studies of treatment efficacy in high inten-
sity populations in Vietnam. In contrast, the higher efficacy of
single dose albendazole would make this a suitable alterna-
tive. There are considerable opportunity costs associated with
well-intentioned widespread use of insufficiently effective an-
tihelmintic treatments, underlining the need for local testing
of anthelmintic efficacy prior to the implementation of na-
tional control programs. More generally, the low efficacy re-
ported here and in some other studies highlights both the
need for monitoring of drug efficacy and possible drug resis-
tance, and the urgent need for research and development of
novel anthelmintic drugs, combination chemotherapy, and al-
ternative methods of control, such as vaccination.24,31–33
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